Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2745203 | 0.86 | PTGS1 (0.58) | ALOX5PTGS1MAPK1ALDH1A1SLC22A12 | |
| SCHEMBL954605 | 0.86 | PTGS1 (0.58) | ALOX5PTGS1MAPK1ALDH1A1SLC22A12 | |
| SCHEMBL1008197 | 0.86 | MAPK1 (0.41) | L3MBTL1MAPK1TSHRTDP1ALDH1A1 | |
| SCHEMBL1135051 | 0.82 | MAPK1 (0.39) | L3MBTL1MAPK1TSHRTDP1ALDH1A1 | |
| SCHEMBL4129278 | 0.81 | L3MBTL1 (0.47) | ALOX5PTGS1L3MBTL1MAPK1TSHR | |
| SCHEMBL3918115 | 0.80 | L3MBTL1 (0.55) | PTGS1L3MBTL1MAPK1TSHRTDP1 | |
| SCHEMBL2745152 | 0.80 | L3MBTL1 (0.49) | L3MBTL1MAPK1TSHRTDP1ALDH1A1 | |
| SCHEMBL2088936 | 0.79 | MAPK1 (0.42) | ALOX5PTGS1MAPK1TSHRALDH1A1 | |
| SCHEMBL956150 | 0.79 | AKR1C3 (0.46) | ALOX5PTGS1SLC22A12FFAR1AKR1C3 | |
| SCHEMBL2745435 | 0.79 | AKR1C3 (0.46) | ALOX5PTGS1SLC22A12FFAR1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2268141-B1 | COMPOUND AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2019-05-08 | — | — | EP | disclosed |
| US-9115072-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-08-25 | — | — | US | disclosed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | disclosed |
| EP-1948152-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8178675-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2268141-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009151695-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090203793-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-08-13 | — | — | US | disclosed |
| EP-1948152-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007056771-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203793-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, CPT1A, GOT2 | ALOX5 311/4885PTGS1 953/4885L3MBTL1 1569/4885 |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | RCC2, HAX1, SLC10A6 | ALOX5 1210/4885PTGS1 2742/4885L3MBTL1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.